Overview

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.
Phase:
PHASE3
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
MK-0616
Rosuvastatin Calcium